证券之星消息，11月18日化学制药板块较上一交易日下跌0.75%，富祥药业领跌。当日上证指数报收于 3939.81，下跌0.81%。深证成指报收于13080.49，下跌0.92%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002020 | 京新药业 | 20.90 | 7.90% | 48.10万 | 10.02亿 | | 000566 | 因曲與 | 8.00 | 7.38% | 337.76万 | 26.98亿 | | 300086 | 康艺药业 | 11.81 | 6.30% | 146.60万 | 17.58亿 | | 002693 | *ST双成 | 8.46 | 4.96% | 27.04万 | 2.28亿 | | 301507 | 民生健康 | 17.61 | 4.14% | 40.27万 | 7.15亿 | | 688197 | 首药控股 | 41.69 | 2.71% | 1.40万 | 5819.19万 | | 301089 | 拓新药业 ...

富祥药业（300497.SZ）11月18日在投资者互动平台表示，公司目前已形成年产8000吨碳酸亚乙烯酯 （VC）产品和约4000吨氟代碳酸乙烯酯（FEC）产品的规模化产能，产品月度实际产量会依据市场需 求与客户订单情况进行科学排产。目前相关产线保持稳定运行。2024年度公司锂电池电解液添加剂产品 出货量达6,525吨，同比增长28%。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司目前每个月vc和FEC的实际产量在多少吨？ ...

Group 1 - On November 17, a total of 12 companies were investigated by institutions, with 6 companies being focused on by funds, including Fuxiang Pharmaceutical, Lingzhi Software, and Fengyuan Co., Ltd. [1] - Fuxiang Pharmaceutical received the most attention, with 12 funds participating in its investigation, while Lingzhi Software and Fengyuan Co., Ltd. had 11 and 5 funds involved, respectively [1][2] - Among the companies investigated, there were 3 from the Shenzhen Main Board, 2 from the ChiNext Board, and 1 from the Sci-Tech Innovation Board [1] Group 2 - In terms of total market capitalization, 2 companies had a market value of less than 10 billion yuan, namely Lingzhi Software and Fengyuan Co., Ltd. [2] - Over the past 5 days, 4 of the investigated stocks increased in value, with Fuxiang Pharmaceutical and Fengyuan Co., Ltd. showing significant gains of 56.90% and 33.24%, respectively [2] - The stocks that experienced declines included Lingzhi Software and Huali Chuantong, with declines of 14.86% and 3.13%, respectively [2][3] Group 3 - The latest closing prices and 5-day price changes for the investigated companies are as follows: Fuxiang Pharmaceutical at 21.15 yuan (+56.90%), Lingzhi Software at 15.13 yuan (-14.86%), Fengyuan Co., Ltd. at 23.85 yuan (+33.24%), and Shiji Information at 10.03 yuan (+7.16%) [3] - The highest net inflow of funds over the past 5 days was seen in Fengyuan Co., Ltd. with 450 million yuan, followed by Guangdong Hongda and Shiji Information with net inflows of 186 million yuan and 94.91 million yuan, respectively [2]

Summary of Fuxiang Pharmaceutical Conference Call Company Overview - Fuxiang Pharmaceutical is the largest supplier of sulbactam and the second-largest supplier of tazobactam globally, focusing on the production of antibiotic intermediates and active pharmaceutical ingredients since 2002 [2][5][22]. Industry Insights - The demand for energy storage and power batteries has significantly increased, leading to a rise in prices for VC (Vinyl Carbonate) and FEC (Fluoroethylene Carbonate) products, supported by government policies [2][3]. - The VC additive market has seen a collective shutdown for maintenance by key players, impacting supply by approximately 20,000 tons [8][10]. Key Points Production Capacity and Expansion Plans - Fuxiang plans to expand VC production capacity to 10,000 tons and FEC to 5,000 tons by Q2 2026, with environmental facilities already prepared for rapid expansion [2][4]. - Current VC production capacity is 8,000 tons, with a cost control below 50,000 yuan per ton, while market prices have surged to around 140,000 yuan [3][14]. Financial Performance and Cost Management - The price of LPA (a key raw material) has decreased from 280,000-300,000 yuan per ton to 160,000-170,000 yuan, significantly improving the gross margins for sulbactam and tazobactam [5][22]. - The company has implemented new processes to reduce costs by approximately 15% and has proprietary technology that is significantly cheaper than external sourcing [24][25]. Market Demand and Product Development - Fuxiang maintains an optimistic outlook on the downstream demand for sulbactam and tazobactam, with annual growth projected in the single digits [22]. - The introduction of new drugs has driven growth in the raw material intermediates market [22]. Microbial Protein and Agricultural Projects - Fuxiang is the first company in China to achieve industrialization of filamentous fungal protein at a scale of over 1,000 tons, with plans to expand to 20,000 tons by 2026 [6][27]. - The company is also developing a water-soluble fertilizer project, expected to yield significant benefits upon completion [28][29]. Competitive Landscape - The competitive landscape in the VC additive market is intense, with Fuxiang's main customers including Tianqi Materials and New Zobang, although specific sales proportions were not disclosed [13]. - The company is well-positioned to respond to market fluctuations due to its existing infrastructure and rapid approval processes for expansion [16][17]. Future Outlook - The company anticipates a new price equilibrium in the market, with strategies in place to maintain competitiveness regardless of price fluctuations [18]. - Fuxiang is closely monitoring developments in solid-state battery materials but currently has no active projects in that area [30]. Additional Insights - The microbial protein market is expected to grow due to its nutritional advantages over plant proteins, including zero cholesterol and low sugar content [30]. - The company has made significant investments in patent protection and certifications to support its strategic direction in microbial protein and other innovative products [7].

Group 1: Market Trends and Demand - The price of VC has rapidly increased, driven by the growth in demand for energy storage and power batteries, with current prices around 50,000 CNY/ton [2][3] - In the first half of 2025, the cumulative sales of power batteries reached 485.5 GWh, a year-on-year increase of 51.6% [3] - The shipment of lithium batteries for energy storage in China was 265 GWh in the first half of 2025, showing a year-on-year growth of 128% [3] Group 2: Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC and 4,000 tons/year for FEC [4] - Plans are in place to increase VC production capacity to 10,000 tons/year by Q2 2026, with potential future expansions to 20,000 tons/year for VC and 5,000 tons/year for FEC depending on market demand [4] Group 3: Pricing and Profitability of Pharmaceutical Products - The procurement price of 6-APA has decreased by 38% compared to the end of 2024, which is expected to enhance the gross margin of the pharmaceutical manufacturing business [6] - The sales revenue from hezobactam and sulbactam is projected to account for approximately 40% of the company's total revenue in 2024 [6] Group 4: Market Outlook for Pharmaceutical Products - The sales of piperacillin-tazobactam injection exceeded 7 billion CNY in 2023, while the sales of cefoperazone-sulbactam injection surpassed 9 billion CNY, marking a year-on-year growth of 13.39% [6] - New drug approvals are expected to drive demand for upstream raw materials and intermediates, opening new growth avenues for the company [6] Group 5: Microbial Protein Production and Future Plans - The company has an existing production capacity of 1,200 tons/year for microbial protein and is accelerating the construction of a project with a planned capacity of 200,000 tons/year [9] - The microbial protein production process is efficient, sustainable, and free from antibiotics, with applications in various sectors including "meat alternatives" and health products [10] Group 6: Advantages of Amino Acid Water-Soluble Fertilizers - The amino acid water-soluble fertilizers contain essential amino acids and have shown significant effects on plant growth and metabolism [11] - The market outlook is promising due to national policies promoting the reduction of chemical fertilizers and the innovation of green inputs [11]

Group 1 - The core point of the article highlights that the main funds in the Shanghai and Shenzhen markets experienced a net outflow of 168.44 billion yuan on November 17, with the ChiNext board seeing a net outflow of 75.05 billion yuan and the CSI 300 index stocks a net outflow of 83.5 billion yuan [2] - Among the 17 industries tracked, 10 industries saw a net inflow of main funds, with the computer industry leading at 43.31 billion yuan, followed by the national defense and military industry at 26.57 billion yuan [2] - The pharmaceutical and biological industry faced the largest net outflow of 62.16 billion yuan, while the electronic industry had a net outflow of 53.12 billion yuan [2] Group 2 - In terms of individual stocks, 94 stocks had a net inflow of over 1 billion yuan, with 20 stocks exceeding 3 billion yuan in net inflow [3] - The stock of Zhongdian Xindong, involved in smart city projects, saw a net inflow of 8.63 billion yuan, marking a significant breakthrough in the urban rail transit sector [3] - Longcheng Military Industry also attracted a net inflow of 7.9 billion yuan, benefiting from a strong opening in the military equipment sector [3] Group 3 - Conversely, 100 stocks experienced a net outflow of over 1 billion yuan, with three leading stocks seeing significant outflows: Ningde Times at 17.62 billion yuan, and both Sunshine Power and Century Huatuo exceeding 10 billion yuan [5] - Century Huatuo's stock hit a limit down, closing with a drop of 9.16% [5] - In the tail end of trading, the total net inflow was 2.96 billion yuan, with Zhongdian Xinchuan leading at 2.6 billion yuan [6][7]

创业板指今日下跌0.20%，报收3105.20点，创业板全日成交额4937.01亿元，比上个交易日减少6.26亿 元。今日可交易创业板股中，813只股收盘上涨，涨幅超过10%的有24只，其中，红相股份、中富通、 江龙船艇等9股涨停，涨幅在5%至10%之间的有52只，收盘下跌的有550只，跌幅超10%的有1只。 证券时报·数据宝统计显示，换手率方面，创业板今日平均换手率为4.18%，换手率区间分布显示，换手 率超过20%的有33只，换手率10%~20%之间的有112只，换手率5%~10%的有229只，换手率1%~5%的有 946只，换手率不足1%的有69只。 交易所公开信息显示，今日高换手率创业板股共有9只上榜龙虎榜，买卖居前营业部中，有5股出现机构 身影，科隆股份有2家机构专用席位上榜，合计净买入832.19万元，清水源有4家机构专用席位上榜，合 计净买入525.88万元，北方长龙有3家机构专用席位上榜，合计净卖出500.63万元，海科新源有4家机构 专用席位上榜，合计净卖出2961.37万元，富祥药业有1家机构专用席位上榜，合计净卖出5354.97万元， 深股通现身2股龙虎榜，江龙船艇获深股通净买入6662 ...

证券之星消息，11月17日化学制药板块较上一交易日下跌1.44%，舒泰神领跌。当日上证指数报收于 3972.03，下跌0.46%。深证成指报收于13202.0，下跌0.11%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300497 | 富祥药业 | 21.15 | 12.14% | 188.67万 | | 38.00亿 | | 000566 | 母南海药 | 7.45 | 10.04% | 256.84万 | | 18.71亿 | | 300086 | 康之约业 | 11.11 | 4.61% | 157.35万 | | 17.47 亿 | | 002020 | 京新药业 | 19.37 | 4.20% | 33.84万 | | 6.65亿 | | 002872 | ST天圣 | 5.70 | 3.07% | 13.65万 | | 7833.29万 | | 301246 | 宏源药业 | 21.39 | 2.74% | 28.03万 | | 5 ...

（文章来源：证券时报网） 据天眼查APP显示，江西富祥药业股份有限公司成立于2002年03月20日，注册资本53864.8934万人民 币。（数据宝） 数据宝统计，截至14:44，富祥药业成交额36.03亿元，创2022年1月21日以来新高。最新股价上涨 12.41%，换手率40.68%。上一交易日该股全天成交额为35.93亿元。 ...

Group 1 - The A-share market saw a rebound in the lithium battery electrolyte concept on November 17, with stocks like Huasheng Lithium rising over 7% after an early drop of more than 10%, reaching a new historical high [1][2] - Yongtai Technology achieved a remarkable performance with 4 consecutive trading limits in 7 days, while Fuxiang Pharmaceutical approached a 20% limit up, indicating strong market interest [1][2] - Other companies such as Kelon Co., Qing Shui Yuan, Haike Xinyuan, Shida Shenghua, and Xinzhou Bang also showed significant gains, reflecting a positive trend in the sector [1][2] Group 2 - According to Baichuan Information, the average transaction price of VC on November 17 was 132,500 yuan per ton, an increase of 25,000 yuan per ton compared to the previous Friday, indicating a strong upward price movement [1][2] - The highest transaction price reached 200,000 yuan per ton, which is an increase of 50,000 yuan per ton from the previous Friday, further highlighting the price surge in the market [1][2]